CD Targeted Cell Therapy Market Size, Share & Trends Analysis Report By Indication Type (Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Lymphoblastic Leukemia, and Others), By Target Type, Region And Segment Forecasts, 2023-2031.

Report Id: 1134 Pages: 180 Published: 08 November 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

The CD Targeted Cell Therapy Market Size is valued at XX Million in 2022 and is predicted to reach XX Million by the year 2031 at an XX % CAGR during the forecast period for 2023-2031.

CD Targeted Cell Therapy Market

InsightAce Analytic’s “Global CD Targeted Cell Therapy Market Research Report 2021” is a comprehensive analysis, forecast, market dynamics, and major trends report, covering critical market data on the CD targeted cell therapy target type segments. This market research report provides market estimation and forecast for value (US$), within CD targeted cell therapy market segments.

CD Targeted Cell Therapies is one of the fastest advancing technology along with huge research and development activities. The oncology market today could be quickly superseded by next-generation therapies in the upcoming forecast period. The CD-targeted cell therapy market is driven by increasing research funding in the immune-oncology, rising prevalence of cancer, and increasing focus on research activities from government health institutions and pharma giants in Immuno-oncology therapy development.

Market Segmentation

The Global CD Targeted Cell Therapy Market is segmented on the basis of indication type, target type, and region. Based on the indication type, the CD targeted cell therapy market is divided into Diffuse large B-cell lymphoma, Chronic lymphocytic leukemia, Multiple myeloma, Acute lymphoblastic leukemia, and Others. Based on the target type, the CD targeted cell therapy market is divided into CD19, CD20, and CD33. Based on region, the market is studied across North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Among that, North America held the largest share of the market, followed by Europe. On the other hand, Asia-Pacific is expected to dominate the CD Targeted Cell Therapy Market during the analysis of the forecast period.

Key insights included in the report

  • This InsightAce Analytic report will help to develop sales strategies by understanding the trends shaping and driving
  • Organize marketing and sales efforts by identifying the best opportunities for CD Targeted Cell Therapy Market
  • This report offers analysis or key insights to understand the future market competition in the CD-targeted cell therapy market.
  • Key features of CD targeted cell therapy product which makes them a better choice over substitute product with the inclusion of Porter’s Five Forces Analysis
  • How did the CD targeted cell therapy market evolve, and what is its scope in the future
  • Key development strategies which the key players implement to maintain and capture market share
  • Analysis of major market drivers, challenges, and opportunities in the global CD targeted cell therapy market
  • Insights on the current leading companies dominating the global CD targeted cell therapy market
  • The market analysis and forecast of the leading segments and sub-segments of the global CD targeted cell therapy industry
  • Analysis of each segment of the global CD targeted cell therapy market expected to grow during the forecast period 2023-2031.
  • Analysis of geographic region that carries the potential for the significant expansion of key companies for CD targeted cell therapy market

Competitive Landscape

Some of The Key Players in The CD Targeted Cell Therapy Market:

  • Juno Therapeutics
  • Agios Pharmaceutical
  • Aurora BioPharma
  • Atara Biotherapeutics
  • AryoGen Biopharma
  • Shenzhen BinDeBio Ltd.
  • China Immunotech Co., Ltd.
  • Autolus Limited
  • Kite Pharma
  • Bellicum Pharmaceuticals
  • bluebird bio
  • Calibr
  • Carina Biotech
  • CARsgen Therapeutics
  • Celgene Corporation
  • Cellectis
  • Cell Medica
  • AbbVie
  • Allogene Therapeutics
  • Amgen
  • Cell Design Labs
  • Celularity
  • Celyad
  • Fate Therapeutics
  • Fortress Bio
  • Gilead Sciences
  • Sorrento Therapeutics, Inc.
  • Ziopharm
  • Janssen Biotech
  • JW Therapeutics
  • Medisix Therapeutics
  • Mustang Bio
  • Nanjing Legend Biotech
  • Precision Biosciences
  • Posedia Therapeutics
  • Other Prominent Players

The CD Targeted Cell Therapy Market Report Scope

Report Attribute Specifications
Market Size Value In 2022 USD XX Million
Revenue Forecast In 2031 USD XX Million
Growth Rate CAGR CAGR of XX % from 2023 to 2031
Quantitative Units Representation of revenue in US$ Million and CAGR from 2023 to 2031
Historic Year 2019 to 2022
Forecast Year 2023-2031
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Indication Type, By Target Type
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia
Competitive Landscape Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Pharma, Bellicum Pharmaceuticals, bluebird bio,Calibr, Carina Biotech, CARsgen Therapeutics, Celgene Corporation, Cellectis, Cell Medica, AbbVie, Allogene Therapeutics, Amgen, Cell Design Labs, Celularity, Celyad, Fate Therapeutics, Fortress Bio, Gilead Sciences, Sorrento Therapeutics, Inc., Ziopharm,Janssen Biotech, JW Therapeutics, Medisix Therapeutics, Mustang Bio, Nanjing Legend Biotech, Precision Biosciences, and Posedia Therapeutics, and Others
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing and Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Global CD Targeted Cell Therapy Market Segmentation:

Global CD Targeted Cell Therapy Market by Indication Type

  • Diffuse large B-cell lymphoma
  • Chronic lymphocytic leukemia
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Others

CD Targeted Cell Therapy Market

Global CD Targeted Cell Therapy Market by Target Type

  • CD19
  • CD20
  • CD33

Global CD Targeted Cell Therapy Market Based on Region

Europe CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • U.S.
  • Canada

Asia Pacific CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2.Executive Summary

Chapter 3.Global CD Targeted Cell Therapy Market Snapshot

Chapter 4.Global CD Targeted Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry

Chapter 5.Market Segmentation 1: By Indication Type Estimates & Trend Analysis
5.1. By Indication Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Indication Type:
5.2.1. Diffuse large B-cell lymphoma
5.2.2. Chronic lymphocytic leukemia
5.2.3. Multiple myeloma
5.2.4. Acute lymphoblastic leukemia
5.2.5. Others

Chapter 6.Market Segmentation 2: By Target Type Estimates & Trend Analysis
6.1. By Target Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Target Type:
6.2.1. CD19
6.2.2. CD20
6.2.3. CD33

Chapter 7.CD Targeted Cell Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Indication Type, 2023-2031
7.1.2. North America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.1.3. North America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
7.1.3.1. U.S.
7.1.3.2. Canada

7.2. Europe
7.2.1. Europe CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, 2023-2031
7.2.2. Europe CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.2.3. Europe CD Targeted Cell Therapy Market revenue (US$ Million) by country, 2023-2031
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe

7.3. Asia Pacific
7.3.1. Asia Pacific CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, 2023-2031
7.3.2. Asia Pacific CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.3.3. Asia Pacific CD Targeted Cell Therapy Market revenue (US$ Million) by country, 2023-2031
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific

7.4. Latin America
7.4.1. Latin America CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, 2023-2031
7.4.2. Latin America CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.4.3. Latin America CD Targeted Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America

7.5. Middle East & Africa
7.5.1. Middle East & Africa CD Targeted Cell Therapy Market revenue (US$ Million) by By Indication Type, (US$ Million)
7.5.2. Middle East & Africa CD Targeted Cell Therapy Market revenue (US$ Million) estimates and forecasts By Target Type, 2023-2031
7.5.3. Middle East & Africa CD Targeted Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2023-2031
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA

Chapter 8.Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles

8.2.1. Juno Therapeutics
8.2.2. Agios Pharmaceutical
8.2.3. Aurora BioPharma
8.2.4. Atara Biotherapeutics
8.2.5. AryoGen Biopharma
8.2.6. Shenzhen BinDeBio Ltd.
8.2.7. China Immunotech Co., Ltd.
8.2.8. Autolus Limited
8.2.9. Kite Pharma
8.2.10. Bellicum Pharmaceuticals
8.2.11. bluebird bio
8.2.12. Calibr
8.2.13. Carina Biotech
8.2.14. CARsgen Therapeutics
8.2.15. Celgene Corporation
8.2.16. Cellectis
8.2.17. Cell Medica
8.2.18. AbbVie
8.2.19. Allogene Therapeutics
8.2.20. Amgen
8.2.21. Cell Design Labs
8.2.22. Celularity
8.2.23. Celyad
8.2.24. Fate Therapeutics
8.2.25. Fortress Bio
8.2.26. Gilead Sciences
8.2.27. Sorrento Therapeutics, Inc.
8.2.28. Ziopharm
8.2.29. Janssen Biotech
8.2.30. JW Therapeutics
8.2.31. Medisix Therapeutics
8.2.32. Mustang Bio
8.2.33. Nanjing Legend Biotech
8.2.34. Precision Biosciences
8.2.35. Posedia Therapeutics
8.2.36. Other Prominent Players

 

Global CD Targeted Cell Therapy Market Segmentation:

Global CD Targeted Cell Therapy Market by Indication Type

  • Diffuse large B-cell lymphoma
  • Chronic lymphocytic leukemia
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Others


Global CD Targeted Cell Therapy Market by Target Type

  • CD19
  • CD20
  • CD33

Global CD Targeted Cell Therapy Market Based on Region

Europe CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • U.S.
  • Canada

Asia Pacific CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa CD Targeted Cell Therapy Market Outlook 2019-2030 by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa
Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
9079
Security Code field cannot be blank!

Frequently Asked Questions

The CD Targeted Cell Therapy Market Size is valued at XX Million in 2022 and is predicted to reach XX Million by the year 2031.

The CD Targeted Cell Therapy Market is expected to grow at an XX % CAGR during the forecast period for 2023-2031.

Juno Therapeutics, Agios Pharmaceutical, Aurora BioPharma, Atara Biotherapeutics, AryoGen Biopharma, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd

Indication Type, and Target Type are the key segments of the CD Targeted Cell Therapy Market.

North American region is leading the CD Targeted Cell Therapy Market.
Get Sample Report Enquiry Before Buying